vs
TFS Financial CORP（TFSL）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
再鼎医药的季度营收约是TFS Financial CORP的1.5倍（$127.1M vs $83.7M），再鼎医药同比增速更快（17.1% vs 11.9%），TFS Financial CORP自由现金流更多（$57.1M vs $-26.7M），过去两年再鼎医药的营收复合增速更高（20.8% vs 4.2%）
TFS金融公司是一家总部位于美国的金融控股企业，主要通过旗下零售银行子公司开展业务，提供住房抵押贷款、储蓄账户及其他消费金融产品，核心客群主要分布于俄亥俄州和佛罗里达州，以个人及家庭客户为服务重心。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
TFSL vs ZLAB — 直观对比
营收规模更大
ZLAB
是对方的1.5倍
$83.7M
营收增速更快
ZLAB
高出5.2%
11.9%
自由现金流更多
TFSL
多$83.8M
$-26.7M
两年增速更快
ZLAB
近两年复合增速
4.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $83.7M | $127.1M |
| 净利润 | $22.3M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | 34.0% | -54.6% |
| 净利率 | 26.6% | — |
| 营收同比 | 11.9% | 17.1% |
| 净利润同比 | -0.7% | — |
| 每股收益（稀释后） | $0.08 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收TFSLZLAB
| Q4 25 | $83.7M | $127.1M | ||
| Q3 25 | $85.5M | $115.4M | ||
| Q2 25 | $82.0M | $109.1M | ||
| Q1 25 | $79.1M | $105.7M | ||
| Q4 24 | $74.8M | $108.5M | ||
| Q3 24 | $75.1M | $101.8M | ||
| Q2 24 | $75.5M | $100.1M | ||
| Q1 24 | $77.1M | $87.1M |
净利润TFSLZLAB
| Q4 25 | $22.3M | — | ||
| Q3 25 | $26.0M | $-36.0M | ||
| Q2 25 | $21.5M | $-40.7M | ||
| Q1 25 | $21.0M | $-48.4M | ||
| Q4 24 | $22.4M | — | ||
| Q3 24 | $18.2M | $-41.7M | ||
| Q2 24 | $20.0M | $-80.3M | ||
| Q1 24 | $20.7M | $-53.5M |
毛利率TFSLZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率TFSLZLAB
| Q4 25 | 34.0% | -54.6% | ||
| Q3 25 | 37.9% | -42.3% | ||
| Q2 25 | 33.3% | -50.3% | ||
| Q1 25 | 33.5% | -53.3% | ||
| Q4 24 | 37.9% | -62.6% | ||
| Q3 24 | 30.7% | -66.6% | ||
| Q2 24 | 33.4% | -76.0% | ||
| Q1 24 | 33.6% | -80.7% |
净利率TFSLZLAB
| Q4 25 | 26.6% | — | ||
| Q3 25 | 30.4% | -31.2% | ||
| Q2 25 | 26.2% | -37.3% | ||
| Q1 25 | 26.6% | -45.8% | ||
| Q4 24 | 30.0% | — | ||
| Q3 24 | 24.2% | -40.9% | ||
| Q2 24 | 26.4% | -80.2% | ||
| Q1 24 | 26.9% | -61.4% |
每股收益（稀释后）TFSLZLAB
| Q4 25 | $0.08 | $-0.05 | ||
| Q3 25 | $0.09 | $-0.03 | ||
| Q2 25 | $0.08 | $-0.04 | ||
| Q1 25 | $0.07 | $-0.04 | ||
| Q4 24 | $0.08 | $-0.09 | ||
| Q3 24 | $0.07 | $-0.04 | ||
| Q2 24 | $0.07 | $-0.08 | ||
| Q1 24 | $0.07 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $456.7M | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.9B | $715.5M |
| 总资产 | $17.5B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资TFSLZLAB
| Q4 25 | $456.7M | $689.6M | ||
| Q3 25 | $429.4M | $717.2M | ||
| Q2 25 | $452.6M | $732.2M | ||
| Q1 25 | $463.6M | $757.3M | ||
| Q4 24 | $465.9M | $779.7M | ||
| Q3 24 | $463.7M | $616.1M | ||
| Q2 24 | $560.4M | $630.0M | ||
| Q1 24 | $594.3M | $650.8M |
股东权益TFSLZLAB
| Q4 25 | $1.9B | $715.5M | ||
| Q3 25 | $1.9B | $759.9M | ||
| Q2 25 | $1.9B | $791.7M | ||
| Q1 25 | $1.9B | $810.8M | ||
| Q4 24 | $1.9B | $840.9M | ||
| Q3 24 | $1.9B | $667.7M | ||
| Q2 24 | $1.9B | $704.2M | ||
| Q1 24 | $1.9B | $762.2M |
总资产TFSLZLAB
| Q4 25 | $17.5B | $1.2B | ||
| Q3 25 | $17.5B | $1.2B | ||
| Q2 25 | $17.4B | $1.2B | ||
| Q1 25 | $17.1B | $1.2B | ||
| Q4 24 | $17.1B | $1.2B | ||
| Q3 24 | $17.1B | $985.3M | ||
| Q2 24 | $17.0B | $987.4M | ||
| Q1 24 | $17.0B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $58.7M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $57.1M | $-26.7M |
| 自由现金流率自由现金流/营收 | 68.2% | -21.0% |
| 资本支出强度资本支出/营收 | 2.0% | 0.5% |
| 现金转化率经营现金流/净利润 | 2.64× | — |
| 过去12个月自由现金流最近4个季度 | $167.4M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流TFSLZLAB
| Q4 25 | $58.7M | $-26.0M | ||
| Q3 25 | $82.4M | $-32.0M | ||
| Q2 25 | $26.8M | $-31.0M | ||
| Q1 25 | $21.2M | $-61.7M | ||
| Q4 24 | $45.5M | $-55.8M | ||
| Q3 24 | $88.6M | $-26.8M | ||
| Q2 24 | $96.7M | $-42.2M | ||
| Q1 24 | $14.2M | $-90.1M |
自由现金流TFSLZLAB
| Q4 25 | $57.1M | $-26.7M | ||
| Q3 25 | $71.0M | $-35.0M | ||
| Q2 25 | $25.0M | $-33.9M | ||
| Q1 25 | $14.3M | $-63.2M | ||
| Q4 24 | $44.9M | $-58.4M | ||
| Q3 24 | $85.5M | $-28.2M | ||
| Q2 24 | $95.9M | $-42.9M | ||
| Q1 24 | $13.4M | $-91.1M |
自由现金流率TFSLZLAB
| Q4 25 | 68.2% | -21.0% | ||
| Q3 25 | 83.0% | -30.4% | ||
| Q2 25 | 30.5% | -31.1% | ||
| Q1 25 | 18.0% | -59.9% | ||
| Q4 24 | 60.0% | -53.8% | ||
| Q3 24 | 113.8% | -27.7% | ||
| Q2 24 | 127.0% | -42.9% | ||
| Q1 24 | 17.4% | -104.5% |
资本支出强度TFSLZLAB
| Q4 25 | 2.0% | 0.5% | ||
| Q3 25 | 13.4% | 2.6% | ||
| Q2 25 | 2.1% | 2.6% | ||
| Q1 25 | 8.8% | 1.5% | ||
| Q4 24 | 0.9% | 2.4% | ||
| Q3 24 | 4.1% | 1.3% | ||
| Q2 24 | 1.1% | 0.7% | ||
| Q1 24 | 1.1% | 1.1% |
现金转化率TFSLZLAB
| Q4 25 | 2.64× | — | ||
| Q3 25 | 3.17× | — | ||
| Q2 25 | 1.24× | — | ||
| Q1 25 | 1.01× | — | ||
| Q4 24 | 2.03× | — | ||
| Q3 24 | 4.86× | — | ||
| Q2 24 | 4.85× | — | ||
| Q1 24 | 0.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
TFSL
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
